• Loading stock data…

Balanced opinions on biotech equities

WHAT YOU GET

Research

Actionable insights into biotech. These are full equity analysis reports on our favorite companies which save our community time and help uncover the 500%+ runners before they run.

Conference Coverage

An overview and in depth reports on our favorite companies attending conferences such as ASH (American Society of Hematology), ASCO (American Society of Clinical Oncology) and more.

FDA Reports

A monthly and weekly overview of upcoming PDUFA's (drug approval decisions), the companies and drugs slated for an FDA decision, and implications on impact stock price and more.

weekly watchlist

Delivered on Sunday,, a watchlist including general market updates and tickers with bullet points on the fundamentals and technical thesis. Includes price targets and more

Webcast Transcripts

Transcripts from recent investor and academic conferences from our favorite names in biotech. Subscribers can also request transcripts from webcasts they would like to review.

chatroom

Exclusive access to our community chatroom where we share findings relevant to our favorite stocks, discuss market conditions, engage with other subscribers, and more.

Frequently asked questions

Our weekly watchlist AKA “Trade Insights,” is an email sent to our members on Sunday night and includes:

  • Market performance and futures for the following day
  • Market update, your overview for general market updates, political and economic. This includes an overview of all upcoming economic reports for the week.
  • Trade candidates for the following day. Here you will find 2 researched tickers which will include bullet points on their fundamentals such as how much cash the company has, the next upcoming catalyst, the companies pipeline and more. You will also find technicals such as support and resistance we are watching as well as a price target range, time, and risk estimate.
  • We have a support team standing by to answer questions when they arise about specific stocks etc on the nightly email

Monthly, and quarterly subscriptions offer the same access. The difference between these subscriptions is the billing schedule. Monthly is billed once per month, quarterly is billed once every 3 months. Quarterly subscriptions offer a discount compared to the monthly subscription. 

Yes, all subscription options offer a free trial. We want to make sure our service is good fit for you! 

  • Monthly: 3 day free trial
  • Quarterly: 1 week free trial

Yes. Once subscribed you can manage your subscription under your profile. Here you will find the option to pause or cancel your subscription. We just ask that you provide some feedback if your willing to help us improve.

what Our subscribers say

I signed up to you guys a few months ago. Excellent insight is provided and some great calls on the daily emails and trading alerts. I would honestly encourage anyone to give them a try
KipperRSA
Monthly Subscriber
When I first got into investments with my inexperience I had lost 90% of my capital. I was discourages from investing for 3-6months. I then met Mr. MS himself. From then on I have regained what I have lost and then some. This is a great supplement to anyones level of trading experience. The cost is an investment
MS SD
Monthly Subscriber
Upon joining I didn't know what to expect. I thought maybe I'll make a few extra bucks and learn something. I started reading the articles and asking questions from Sultan and before I knew it I was making some serious profits! I just follow what the articles say, ask questions when they arise and keep taking profits!
MS SD
Monthly Subscriber
I was a complete stock noob; I knew nothing about stocks before using MS Money Moves. It’s been about 4 months, and I still don’t know all that much BUT my initial investment has TRIPLED. Sultan has always been there to answer questions and put me on the right track. He’s a great help and the amount of dedication and work he puts in on the articles and reports.. honestly mind-blowing. Bottom line, sign up and be patient. It’s a tiny fee for the returns you’ll be seeing.
Michael L
Quarterly Subscriber
I signed up last week for a quarterly subscription. Today was my first day trading on their recommendations, made $167 on CEMI, $182 on VCNX, $50 on AIM, $44 on TRVN, down $54 on KRMD. So my first day I pad for my quarterly membership and got some extra cash. Didn't go in heavy while testing it out but I will be next time.
Stonehousebullmug
Quarterly subscriber

Choose your plan

$39.69

every month

$99.69

Every 3months

Disclaimer

MS Money Moves/Biotechwinners, its operators, and their affiliates are individual investors sharing their thoughts on biotech/life-sciences companies they are interested in. This should not be taken as financial advice, please consult YOUR financial advisor or other trusted financial professional before making investment decisions.

Our content should serve as educational material to help you while conducting your due diligence. Articles and emails are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action. The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.